Lodalis · DIN 02373955 · 625 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lodalis · DIN 02373955
Manufacturer: Valeant Canada Ltd.; listing date 2014-05-29
Health Canada: Marketed since 2020-12-09 · brand LODALIS · ATC C10AC04 COLESEVELAM · form Tablet · route Oral · ingredients COLESEVELAM HYDROCHLORIDE 625 MG · company Bausch health, canada inc. · schedule Prescription
Ministry pays: $0.5931 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02373955)
Source record
DIN 02373955: Lodalis
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600072; group id 300; item number 0653; lccId None; manufacturer id VAL
Source form: Tab; strength: 625mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4184; ministry $0.5931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02373955
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85917
Therapeutic Notes (formulary)
Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:
. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
or
. who are unable to tolerate a statin.
Interchangeable products
Apo-Colesevelam · DIN 02494051 · $0.5931
Shortage status: resolved shortage (ended March 25, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373955
Shortage record checked October 6, 2026